Replies to post #228428 on Biotech Values

[DewDiligence]

BMY will get a royalty on XLRN’s sotatercept potential sales in PAH—(according to a 2019 amendment to a 2008 partnership):

http://investor.acceleronpharma.com/news-releases/news-release-details/acceleron-develop-sotatercept-pulmonary-arterial-hypertension

Acceleron Pharma Inc…today announced it has amended the sotatercept development and commercialization collaboration agreement with Celgene Corporation, originally executed on February 20, 2008. The amended agreement provides Acceleron with global access to sotatercept for development and commercialization in pulmonary arterial hypertension (PAH).

…Under the amended and restated collaboration agreement, Acceleron has the right to fund and conduct all research and development activities for sotatercept in the pulmonary hypertension field. Should sotatercept be approved for an indication in the pulmonary hypertension field, Acceleron will be responsible for global commercialization and Celgene will be eligible to receive royalties on global net sales in that field. The original collaboration deal terms will remain in place with respect to development and commercialization outside of the pulmonary hypertension field.